Eiger BioPharmaceuticals, Inc.
Other OTCTotal Valuation
Eiger BioPharmaceuticals, Inc. carries a market capitalization of 12.59M, placing it among publicly traded companies globally. Its enterprise value stands at 25.72M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 12.59M |
| Enterprise Value | 25.72M |
Share Statistics
Eiger BioPharmaceuticals, Inc. currently has 1.48M shares outstanding.
| Shares Outstanding | 1.48M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.63, and the price-to-book ratio stands at -0.02.
| PE Ratio | N/A |
| PS Ratio | 0.63 |
| PB Ratio | -0.02 |
| P/TBV Ratio | -0.69 |
| P/FCF Ratio | -0.13 |
| P/OCF Ratio | -0.13 |
Enterprise Valuation
| EV / Sales | 1.63 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Eiger BioPharmaceuticals, Inc. maintains a current ratio of 0.71, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -284.98, indicating conservative leverage, while an interest coverage ratio of -13.00 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.71 |
| Quick Ratio | 0.51 |
| Debt / Equity | -284.98 |
| Debt / EBITDA | -0.58 |
| Interest Coverage | -13.00 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -94.31 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.01 |
Taxes
| Income Tax | 6,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Eiger BioPharmaceuticals, Inc.'s stock has gained approximately 3.7851% over the past 52 weeks. The 50-day moving average sits at 11.27, while the 200-day moving average is 6.94.
| Beta (5Y) | N/A |
| 52-Week Price Change | 3.7851% |
| 50-Day Moving Average | 11.27 |
| 200-Day Moving Average | 6.94 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Eiger BioPharmaceuticals, Inc. generated 15.77M in revenue and converted that into -74.96M in net income, yielding earnings per share of -50.82. EBITDA reached -71.04M, while operating income came in at -71.79M.
| Revenue | 15.77M |
| Gross Profit | 15.75M |
| Operating Income | -71.79M |
| Pretax Income | -74.96M |
| Net Income | -74.96M |
| EBITDA | -71.04M |
| EBIT | -71.79M |
| Earnings Per Share (EPS) | -50.82 |
Balance Sheet
Eiger BioPharmaceuticals, Inc. holds 25.44M in cash and equivalents against 41.20M in total debt, resulting in a net debt position of 15.68M. Total book value stands at -512.15M, with working capital of -15.44M providing operational flexibility.
| Cash & Cash Equivalents | 25.44M |
| Total Debt | 41.20M |
| Net Debt | 15.68M |
| Equity (Book Value) | -512.15M |
| Book Value Per Share | -347.19 |
| Working Capital | -15.44M |
Cash Flow
Eiger BioPharmaceuticals, Inc. produced -74.55M in operating cash flow over the past twelve months. After subtracting -234,000.00 in capital expenditures, free cash flow totaled -74.78M - equivalent to -50.70 per share.
| Operating Cash Flow | -74.55M |
| Capital Expenditures | -234,000.00 |
| Free Cash Flow | -74.78M |
| FCF Per Share | -50.70 |
Margins
Eiger BioPharmaceuticals, Inc. operates with a gross margin of 99.85, reflecting its pricing power and cost economics. The operating margin of -455.12 and net profit margin of -475.26 provide insight into operational efficiency.
| Gross Margin | 99.85 |
| Operating Margin | -455.12 |
| Pretax Margin | -475.22 |
| Profit Margin | -475.26 |
| EBITDA Margin | -450.36 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.41 |
| FCF Yield | -746.34 |
Stock Splits
Eiger BioPharmaceuticals, Inc.'s most recent stock split took place on January 8, 2024 with a 30:1 split ratio.
| Last Split Date | 1/8/2024 |
| Split Ratio | 30:1 |
Scores
Eiger BioPharmaceuticals, Inc. posts an Altman Z-Score of -24.53, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -24.53 |